Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

Take this quiz to test your comprehension of one of our recent feature articles.

Test Your Knowledge: Patient-Centric Care Through Oral Liquid Delivery

Test Your Knowledge (Answers): Patient-Centric Care Through Oral Liquid Delivery

Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.

Why Radiopharmaceuticals Are Ideal for Treating Cancer

Hibreniguss Terefe, is director, Product Development Somerset Ardena.

This article outlines common CMC problems that are obstacles that steal momentum and create costly detours in the development or orphan drugs.

The Push for Momentum, Not Mistakes in Orphan Drug Development

Cheryl Barton is director of PharmaVision, 

The European Union aims to become the most attractive place for life science by 2030.

European Union Life Science Strategy

Data from four major pivotal trials will be shared, but AstraZeneca medications and pipeline molecules appear in more than 90 abstracts for the upcoming conference in Berlin.

AstraZeneca’s Cancer Care Contributions to be Highlighted with Trial Data at ESMO Congress

Mike Hennessy Jr. is the Chairman and CEO of 

This issue showcases strategies that organizations are adopting to stay competitive as pressing industry trends shape the sector.

From Discovery to Delivery: Evolving Practices in Pharma

Akanksha Prasad, MS, is a chemical and bioprocess engineer with over nine years of experience in chemical, biologics, and pharmaceutical process development. Her expertise spans mRNA, vaccines, and biologics, with a focus on technology transfer, PAT, scale-up, purification, and regulatory compliance. She holds a Master’s in Chemical Engineering with a biopharma specialization from the Illinois Institute of Technology, Chicago, and a Bachelor’s in Chemical Engineering from India.

This paper provides an in-depth overview of the anatomical structure and functional dynamics of renal filtration, secretion, and reabsorption processes that govern drug clearance.

Mechanistic Modeling of Renal Clearance: Optimizing Dosing Strategies for Elderly Patients

US President Donald Trump made the announcement that AstraZeneca is the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation pricing protocols.

AstraZeneca Is Next to Reach MFN Deal with White House

AstraZeneca’s $4.5 billion investment in Virginia expands its US drug manufacturing footprint, creating 3600 jobs and integrating AI for cancer and metabolic therapies.